Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
Sponsorprof. dr. Rik Schrijvers
About this trial
The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy
Eligibility criteria
Qualifiers
Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway.
Healthy controls (without immune-mediated disease)
Disqualifiers
Children (< 18 years at time of recruitment)
Persons unable or unwilling to give informed consent
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
prof. dr. Rik Schrijvers
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Sponsor institution
Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek)
Collaborator
Source ClinicalTrials.gov